Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,071 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, Ohtsuka E, Yoshida T, Higuchi M, Yoshimoto G, Fujisaki T, Abe Y, Takamatsu Y, Yokota S, Akashi K, Harada M. Nagafuji K, et al. Among authors: higuchi m. J Hematol Oncol. 2013 Feb 6;6:14. doi: 10.1186/1756-8722-6-14. J Hematol Oncol. 2013. PMID: 23388549 Free PMC article.
Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
Gondo H, Himeji D, Kamezaki K, Numata A, Tanimoto T, Takase K, Aoki K, Henzan H, Nagafuji K, Miyamoto T, Ishikawa F, Shimoda K, Inaba S, Tsukamoto H, Horiuchi T, Nakashima H, Otsuka T, Kato K, Kuroiwa M, Higuchi M, Shibuya T, Kamimura T, Kuzushima K, Tsurumi T, Kanda Y, Harada M. Gondo H, et al. Among authors: higuchi m. Int J Hematol. 2004 Dec;80(5):441-8. doi: 10.1532/ijh97.04109. Int J Hematol. 2004. PMID: 15646657
Demonstration of reversed flow in segmental branches of the portal vein with hand-held color Doppler ultrasonography after hematopoietic stem cell transplantation.
Hashiguchi M, Okamura T, Yoshimoto K, Ono N, Imamura R, Yakushiji K, Ogata H, Seki R, Otsubo K, Oku E, Kuroiwa M, Higuchi M, Kato K, Taniguchi S, Gondo H, Shibuya T, Nagafuji K, Harada M, Sata M. Hashiguchi M, et al. Among authors: higuchi m. Bone Marrow Transplant. 2005 Dec;36(12):1071-5. doi: 10.1038/sj.bmt.1705170. Bone Marrow Transplant. 2005. PMID: 16247437
Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan.
Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S, Uchida T, Kishi K, Tanaka Y, Kohno A, Kasai M, Higuchi M, Kasai M, Mori S, Fukuda T, Izutsu K, Sao H, Ishikawa T, Ichinohe T, Takeuchi K, Tajima K, Tanosaki R, Harada M, Taniguchi S, Tobinai K, Hotta T, Takaue Y. Kim SW, et al. Among authors: higuchi m. Blood. 2006 Jul 1;108(1):382-9. doi: 10.1182/blood-2005-02-0596. Epub 2006 Mar 7. Blood. 2006. PMID: 16522821 Free article.
Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T. Seki R, et al. Among authors: higuchi m. Cancer Sci. 2009 Oct;100(10):1842-7. doi: 10.1111/j.1349-7006.2009.01268.x. Epub 2009 Jul 1. Cancer Sci. 2009. PMID: 19656156 Free PMC article.
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.
Seki R, Ohshima K, Nagafuji K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T. Seki R, et al. Among authors: higuchi m. Int J Hematol. 2010 Mar;91(2):258-66. doi: 10.1007/s12185-009-0475-2. Int J Hematol. 2010. PMID: 20066574
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Takamatsu Y, Sunami K, Hata H, Nagafuji K, Choi I, Higuchi M, Uozumi K, Masaki Y, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Among authors: higuchi m. Int J Hematol. 2010 Oct;92(3):503-9. doi: 10.1007/s12185-010-0673-y. Epub 2010 Sep 8. Int J Hematol. 2010. PMID: 20824401 Clinical Trial.
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
Takamatsu Y, Sunami K, Muta T, Morimoto H, Miyamoto T, Higuchi M, Uozumi K, Hata H, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Among authors: higuchi m. Int J Hematol. 2013 Aug;98(2):179-85. doi: 10.1007/s12185-013-1389-6. Epub 2013 Jul 6. Int J Hematol. 2013. PMID: 23832805 Clinical Trial.
Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
Yamasaki S, Yoshimoto G, Ogawa R, Aoki K, Higuchi M, Harada N, Arima F, Kondo S, Matubara F, Takahashi T, Uike N, Miyamoto T, Okamura S, Akashi K; Fukuoka Blood and Marrow Transplantation Group. Yamasaki S, et al. Among authors: higuchi m. Ann Hematol. 2015 Jul;94(7):1159-65. doi: 10.1007/s00277-015-2338-7. Epub 2015 Feb 24. Ann Hematol. 2015. PMID: 25704584
2,071 results